[PMC free article] [PubMed] [Google Scholar] 113.Kang Q., Dai H., Jiang S., Yu L
Interestingly, we detected increased total ATP in Gclc -deficient FoB (Fig
In 2025, Wegovy was also approved for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease
Ludwig, E
Acknowledgments I wish to thank Vincent Feuillet for the quality of the figures, Dominique Salmon for fruitful discussions, Lisa Chakrabarti, Morgane Bomsel, Pierre Sujobert, Alain Marty and Tomaso Antonacci for critical reading of the manuscript
Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study